With information from the latest evidence-based studies, participants should be able to:

• Describe the effects of ezetimibe plus simvastatin on atherosclerotic progression in patients with familial hypercholesterolemia 
• Recognize the association between lipoprotein(a) levels and future coronary heart disease (CHD) risk
• Delineate the relationships of plasma HDL cholesterol levels, HDL particle size, and apolipoprotein A-I with CHD risk

Click here to listen to this podcast. (Or, to download the audio file, right click on the link and choose "Save Target As".)

With information from the latest evidence-based studies, participants should be able to: 

• Describe the effects of different dyslipidemia phenotypes from childhood to adulthood and their interaction with nonlipid risk factors on markers of subclinical atherosclerosis
• Compare the usefulness of the triglyceride/high-density lipoprotein (HDL) ratio versus the total cholesterol/HDL ratio for predicting insulin resistance and cardiometabolic risk
• Access the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension and dyslipidemia in African American patients with risk of cardiovascular disease